Examkin

Soru

Zorluk: ZorPharmacologic Interventions

A 34-year-old woman is evaluated in the outpatient clinic for follow-up of a deep vein thrombosis (DVT). Three days ago, she presented to the emergency department with left leg swelling and was diagnosed with an unprovoked left popliteal DVT. She was discharged with a prescription for rivaroxaban. Her past medical history is significant for systemic lupus erythematosus (SLE) with polyarthritis, well-controlled on hydroxychloroquine. She also has a history of two consecutive spontaneous abortions at 10 and 12 weeks of gestation. Current medications are rivaroxaban and hydroxychloroquine. Vital signs are within normal limits. Physical examination shows mild left lower extremity pitting edema.

Laboratory studies obtained during the emergency department visit are reviewed:
Hemoglobin: 12.2 g/dL
Platelet count: 130,000/mm³
Prothrombin time (PT): 13 seconds (normal: 11-15 seconds)
Activated partial thromboplastin time (aPTT): 62 seconds (normal: 25-40 seconds)

A 1:1 mixing study with normal plasma yields an aPTT of 58 seconds.

Which of the following is the most appropriate pharmacologic intervention for this patient's deep vein thrombosis?

  1. Discontinue rivaroxaban and initiate enoxaparin bridged to warfarinCevap
  2. B
    Continue current rivaroxaban therapy and add low-dose aspirin
  3. C
    Discontinue rivaroxaban and initiate apixaban
  4. D
    Discontinue rivaroxaban and initiate argatroban
  5. E
    Discontinue rivaroxaban and initiate dual antiplatelet therapy with aspirin and clopidogrel

Cevap

The most appropriate intervention is to discontinue rivaroxaban and initiate enoxaparin bridged to warfarin.
The correct intervention requires recognizing that this patient has Antiphospholipid Syndrome (APS), characterized by recurrent miscarriages, SLE, and a lupus anticoagulant (demonstrated by the uncorrected prolonged aPTT on a mixing study). For patients with APS who develop venous thromboembolism, direct oral anticoagulants (DOACs) like rivaroxaban are contraindicated due to a significantly higher risk of recurrent thromboembolic events compared to vitamin K antagonists. Therefore, the standard of care is to immediately discontinue the DOAC and initiate an overlapping bridge of low-molecular-weight heparin (e.g., enoxaparin) and warfarin until a therapeutic INR is achieved.

Adım Adım Çözüm

1
Analyze the patient's history and lab findings to establish the underlying diagnosis.
The patient has SLE, recurrent mid-trimester miscarriages, and an isolated prolonged aPTT that fails to correct with a 1:1 mixing study.
Failure to correct on a mixing study indicates the presence of an inhibitor (in this case, lupus anticoagulant) rather than a factor deficiency. Combined with her clinical history, this confirms a diagnosis of Antiphospholipid Syndrome (APS).
2
Evaluate the current pharmacologic management for venous thromboembolism (VTE) in the context of the newly established diagnosis.
The patient is currently taking rivaroxaban, a direct oral anticoagulant (DOAC).
DOACs have been shown in randomized trials (e.g., TRAPS) to have unacceptably high rates of recurrent arterial and venous thrombosis in patients with APS compared to vitamin K antagonists.
3
Select the safest, guideline-concordant pharmacologic intervention.
Warfarin therapy is selected as the definitive treatment.
Because warfarin requires several days to achieve therapeutic anticoagulation, the patient must be bridged with a parenteral anticoagulant such as low-molecular-weight heparin (enoxaparin) until the INR is therapeutic.

Anahtar Kavram

Direct oral anticoagulants (DOACs) are contraindicated for the treatment of venous thromboembolism in patients with Antiphospholipid Syndrome (APS); these patients require treatment with low-molecular-weight heparin bridged to warfarin.

Alternatif Yöntem

When evaluating a prolonged aPTT, remembering the 'mixing study rule' rapidly narrows the differential: if it corrects, it is a factor deficiency (e.g., hemophilia); if it fails to correct, it is an inhibitor (e.g., lupus anticoagulant or specific factor inhibitor).
Tahmini Süre:1m 30s
Bu soruyu puanla

Konular

Pharmacologic Interventions

Bu konudan daha fazla soru